Cervical Dystonia Management Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023
Cervical Dystonia Management Market
Cervical dystonia, also known as spasmodic torticollis, rare neurological disorder that originates in the brain. Cervical dystonia is characterized by involuntary muscle contractions in the neck that cause abnormal movements and postures of the neck and head. The severity of cervical dystonia can vary, but the disorder can cause significant pain and discomfort as well as difficulty due to the abnormal postures. It can affect the quality of life and activities of daily living including employment. Cervical dystonia typically begins in middle age, and rarely begins in adolescence and young adulthood. The cause of cervical dystonia is unknown, although a genetic susceptibility is thought to underlie some cases.
The major driving factors for the market for cervical dystonia market is increase in aging population across the globe. Females are more likely to be get affected by cervical dystonia. Besides this increase in treatment for cervical dystonia and improvement in infrastructure provided fuel for the growth of the market. Furthermore, low and increase in cost of treatment is the major cause for restraining the growth of cervical dystonia market.
Cervical Dystonia Management Market segmented on the basis of cervical dystonia type, route of administration, drug class, distribution channel, and region.
Based on the route of administration, it is segmented as:
Oral
Intravenous
Based on the drug class, it is segmented as:
Dopaminergic drugs
Anti-cholinergic drugs
GABA Agonists
Anti Convulsants
Based on the distribution channel, it is segmented as:
Hospital pharmacies
Retail pharmacies
Others
According to the Association of neurological American Surgeons about 250,000 people are having cervical dystonia every year. According to National organization for rare diseases (NORD) it is anticipated that around 60,000 individuals in US are suffering with cervical dystonia
On a regional basis, global cervical dystonia market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The market is dominated by North America due to developed infrastructure, governmental initiatives, and increase in demand for the better treatment of cervical dystonia driving factor in North America. Furthermore, increase in aging population in Canada fuelling the growth of North America cervical dystonia market. Europe and Asia-Pacific accounts to have significant market share. However, Asia-Pacific expected to dominate the market in the forecast period due to continuous development and increase in cervical dystonia treatment procedures. Furthermore, large patient pool in Asia-Pacific region contributes significant growth for cervical dystonia market.
Some of the players in cervical dystonia management market are ALLERGAN (Ireland), US WorldMeds (U.S.), Ipsen (France), Addex Therapeutics (Switzerland), and Revance Therapeutics Inc. (U.S.)
InMarch, 2017, Ipsen Biopharmaceuticals Inc., the Canadian affiliate of Ipsen has received Health Canada approval for DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) to treat cervical dystonia.
In 2010, Merz Pharmaceuticals received USFDA approval fo Xeomin® (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm
Cervical dystonia, also known as spasmodic torticollis, rare neurological disorder that originates in the brain. Cervical dystonia is characterized by involuntary muscle contractions in the neck that cause abnormal movements and postures of the neck and head. The severity of cervical dystonia can vary, but the disorder can cause significant pain and discomfort as well as difficulty due to the abnormal postures. It can affect the quality of life and activities of daily living including employment. Cervical dystonia typically begins in middle age, and rarely begins in adolescence and young adulthood. The cause of cervical dystonia is unknown, although a genetic susceptibility is thought to underlie some cases.
The major driving factors for the market for cervical dystonia market is increase in aging population across the globe. Females are more likely to be get affected by cervical dystonia. Besides this increase in treatment for cervical dystonia and improvement in infrastructure provided fuel for the growth of the market. Furthermore, low and increase in cost of treatment is the major cause for restraining the growth of cervical dystonia market.
Cervical Dystonia Management Market segmented on the basis of cervical dystonia type, route of administration, drug class, distribution channel, and region.
Based on the route of administration, it is segmented as:
Oral
Intravenous
Based on the drug class, it is segmented as:
Dopaminergic drugs
Anti-cholinergic drugs
GABA Agonists
Anti Convulsants
Based on the distribution channel, it is segmented as:
Hospital pharmacies
Retail pharmacies
Others
According to the Association of neurological American Surgeons about 250,000 people are having cervical dystonia every year. According to National organization for rare diseases (NORD) it is anticipated that around 60,000 individuals in US are suffering with cervical dystonia
On a regional basis, global cervical dystonia market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The market is dominated by North America due to developed infrastructure, governmental initiatives, and increase in demand for the better treatment of cervical dystonia driving factor in North America. Furthermore, increase in aging population in Canada fuelling the growth of North America cervical dystonia market. Europe and Asia-Pacific accounts to have significant market share. However, Asia-Pacific expected to dominate the market in the forecast period due to continuous development and increase in cervical dystonia treatment procedures. Furthermore, large patient pool in Asia-Pacific region contributes significant growth for cervical dystonia market.
Some of the players in cervical dystonia management market are ALLERGAN (Ireland), US WorldMeds (U.S.), Ipsen (France), Addex Therapeutics (Switzerland), and Revance Therapeutics Inc. (U.S.)
InMarch, 2017, Ipsen Biopharmaceuticals Inc., the Canadian affiliate of Ipsen has received Health Canada approval for DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) to treat cervical dystonia.
In 2010, Merz Pharmaceuticals received USFDA approval fo Xeomin® (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm
1. EXECUTIVE SUMMARY
2. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET INTRODUCTION
2.1. Global Cervical Dystonia Management Market – Taxonomy
2.2. Global Cervical Dystonia Management Market –Definitions
2.2.1. Route of Administration
2.2.2. Drug Class
2.2.3. Distribution Channel
3. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cervical Dystonia Management Market Dynamic Factors - Impact Analysis
3.6. Global Cervical Dystonia Management Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.7. Global Cervical Dystonia Management Market –Trends
4. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Oral
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Intravenous
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET FORECAST, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 – 2023
6.1. Dopaminergic drugs
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Anti-cholinergic drugs
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. GABA Agonists
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Anti Convulsants
6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 – 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
8.1. North America
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Region, 2017 – 2023
9. NORTH AMERICA CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Oral
9.1.2. Intravenous
9.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Dopaminergic drugs
9.2.2. Anti-cholinergic drugs
9.2.3. GABA Agonists
9.2.4. Anti Convulsants
9.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital pharmacies
9.3.2. Retail pharmacies
9.3.3. Others
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023
9.6. North America Cervical Dystonia Management Market Dynamics – Trends
10. EUROPE CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Oral
10.1.2. Intravenous
10.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Dopaminergic drugs
10.2.2. Anti-cholinergic drugs
10.2.3. GABA Agonists
10.2.4. Anti Convulsants
10.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital pharmacies
10.3.2. Retail pharmacies
10.3.3. Others
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023
10.6. Europe Cervical Dystonia Management Market Dynamics – Trends
11. ASIA-PACIFIC CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Oral
11.1.2. Intravenous
11.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Dopaminergic drugs
11.2.2. Anti-cholinergic drugs
11.2.3. GABA Agonists
11.2.4. Anti Convulsants
11.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital pharmacies
11.3.2. Retail pharmacies
11.3.3. Others
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023
11.6. Asia-Pacific Cervical Dystonia Management Market Dynamics – Trends
12. LATIN AMERICA CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Oral
12.1.2. Intravenous
12.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Dopaminergic drugs
12.2.2. Anti-cholinergic drugs
12.2.3. GABA Agonists
12.2.4. Anti Convulsants
12.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital pharmacies
12.3.2. Retail pharmacies
12.3.3. Others
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023
12.6. Latin America Cervical Dystonia Management Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Oral
13.1.2. Intravenous
13.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Dopaminergic drugs
13.2.2. Anti-cholinergic drugs
13.2.3. GABA Agonists
13.2.4. Anti Convulsants
13.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital pharmacies
13.3.2. Retail pharmacies
13.3.3. Others
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023
13.6. MEA Cervical Dystonia Management Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Route of Administration & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Ashland Inc.(U.S.)
14.2.2. AkzoNobel (Netherlands)
14.2.3. The DOW Chemical Company (U.S.)
14.2.4. Archer Daniels Midland Company(U.S.)
14.2.5. Associated British Foods PLC (UK)
14.2.6. Colorcon, Inc.(U.S.)
14.2.7. BASF SE(Germany)
14.2.8. Evonik Industries AG (Germany)
14.2.9. Innophos Holdings Inc. (U.S.)
14.2.10. J.M. Huber Corporation (U.S.)
14.2.11. FMC Corporation (U.S.)
14.2.12. Roquette Group (France)
14.2.13. Croda International PLC (UK)
14.2.14. Merck KGaA (Germany)
14.2.15. Lubrizol Corporation (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET INTRODUCTION
2.1. Global Cervical Dystonia Management Market – Taxonomy
2.2. Global Cervical Dystonia Management Market –Definitions
2.2.1. Route of Administration
2.2.2. Drug Class
2.2.3. Distribution Channel
3. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cervical Dystonia Management Market Dynamic Factors - Impact Analysis
3.6. Global Cervical Dystonia Management Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.7. Global Cervical Dystonia Management Market –Trends
4. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Oral
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Intravenous
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET FORECAST, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 – 2023
6.1. Dopaminergic drugs
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Anti-cholinergic drugs
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. GABA Agonists
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Anti Convulsants
6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 – 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
8.1. North America
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Region, 2017 – 2023
9. NORTH AMERICA CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Oral
9.1.2. Intravenous
9.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Dopaminergic drugs
9.2.2. Anti-cholinergic drugs
9.2.3. GABA Agonists
9.2.4. Anti Convulsants
9.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital pharmacies
9.3.2. Retail pharmacies
9.3.3. Others
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023
9.6. North America Cervical Dystonia Management Market Dynamics – Trends
10. EUROPE CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Oral
10.1.2. Intravenous
10.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Dopaminergic drugs
10.2.2. Anti-cholinergic drugs
10.2.3. GABA Agonists
10.2.4. Anti Convulsants
10.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital pharmacies
10.3.2. Retail pharmacies
10.3.3. Others
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023
10.6. Europe Cervical Dystonia Management Market Dynamics – Trends
11. ASIA-PACIFIC CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Oral
11.1.2. Intravenous
11.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Dopaminergic drugs
11.2.2. Anti-cholinergic drugs
11.2.3. GABA Agonists
11.2.4. Anti Convulsants
11.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital pharmacies
11.3.2. Retail pharmacies
11.3.3. Others
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023
11.6. Asia-Pacific Cervical Dystonia Management Market Dynamics – Trends
12. LATIN AMERICA CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Oral
12.1.2. Intravenous
12.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Dopaminergic drugs
12.2.2. Anti-cholinergic drugs
12.2.3. GABA Agonists
12.2.4. Anti Convulsants
12.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital pharmacies
12.3.2. Retail pharmacies
12.3.3. Others
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023
12.6. Latin America Cervical Dystonia Management Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Oral
13.1.2. Intravenous
13.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Dopaminergic drugs
13.2.2. Anti-cholinergic drugs
13.2.3. GABA Agonists
13.2.4. Anti Convulsants
13.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital pharmacies
13.3.2. Retail pharmacies
13.3.3. Others
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023
13.6. MEA Cervical Dystonia Management Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Route of Administration & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Ashland Inc.(U.S.)
14.2.2. AkzoNobel (Netherlands)
14.2.3. The DOW Chemical Company (U.S.)
14.2.4. Archer Daniels Midland Company(U.S.)
14.2.5. Associated British Foods PLC (UK)
14.2.6. Colorcon, Inc.(U.S.)
14.2.7. BASF SE(Germany)
14.2.8. Evonik Industries AG (Germany)
14.2.9. Innophos Holdings Inc. (U.S.)
14.2.10. J.M. Huber Corporation (U.S.)
14.2.11. FMC Corporation (U.S.)
14.2.12. Roquette Group (France)
14.2.13. Croda International PLC (UK)
14.2.14. Merck KGaA (Germany)
14.2.15. Lubrizol Corporation (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
